{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:10:45Z","timestamp":1789949445614,"version":"4.0.1"},"reference-count":118,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Spanish \u201cInstituto de Salud Carlos III\u201d","award":["FIS PI12\/00380"],"award-info":[{"award-number":["FIS PI12\/00380"]}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["SAF2013-40620-R"],"award-info":[{"award-number":["SAF2013-40620-R"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["FMM-XII-2015\/OBS-IBSAL"],"award-info":[{"award-number":["FMM-XII-2015\/OBS-IBSAL"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Le\u00f3n","doi-asserted-by":"crossref","award":["SA015U13"],"award-info":[{"award-number":["SA015U13"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Le\u00f3n","doi-asserted-by":"crossref","award":["BIO\/SA65\/13"],"award-info":[{"award-number":["BIO\/SA65\/13"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Le\u00f3n","doi-asserted-by":"crossref","award":["BIO\/SA23\/14"],"award-info":[{"award-number":["BIO\/SA23\/14"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.blre.2015.08.001","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T01:15:59Z","timestamp":1439860559000},"page":"55-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia"],"prefix":"10.1016","volume":"30","author":[{"given":"Jose J.G.","family":"Marin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Briz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rodr\u00edguez-Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"D\u00edez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio I.R.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2015.08.001_bb0005","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1182\/blood-2005-02-0711","article-title":"PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism","volume":"106","author":"Walter","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0010","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.18632\/oncotarget.2407","article-title":"Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition","volume":"5","author":"Sison","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2015.08.001_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation.V2012.1.1.3797038","article-title":"Treatment of acute myeloid leukemia: are we making progress?","volume":"2012","author":"Burnett","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2015.08.001_bb0020","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.2012.064014","article-title":"Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study","volume":"98","author":"Maynadie","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2015.08.001_bb0025","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.28129","article-title":"Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades","volume":"119","author":"Thein","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2015.08.001_bb0030","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2009.25.5158","article-title":"Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia","volume":"28","author":"Gore","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2015.08.001_bb0035","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0040","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0268-960X(03)00040-7","article-title":"Cytogenetics in acute leukemia","volume":"18","author":"Mrozek","year":"2004","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2015.08.001_bb0050","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0055","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.blre.2015.08.001_bb0060","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood.V65.6.1407.bloodjournal6561407","article-title":"High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study","volume":"65","author":"Wolff","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0065","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.V77.7.1429.1429","article-title":"High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults","volume":"77","author":"Phillips","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.21543","article-title":"High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials","volume":"107","author":"Kern","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2015.08.001_bb0075","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","article-title":"Cytarabine dose for acute myeloid leukemia","volume":"364","author":"Lowenberg","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2015.08.001_bb0080","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2141.1998.00948.x","article-title":"A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia","volume":"103","author":"Group","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2015.08.001_bb0085","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2015.08.001_bb0090","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"Lowenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2015.08.001_bb0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V75.1.27.27","article-title":"Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group","volume":"75","author":"Bishop","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0100","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.1991.9.7.1210","article-title":"Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia","volume":"9","author":"Amadori","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2015.08.001_bb0105","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/blood.V77.9.1894.1894","article-title":"Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia","volume":"77","author":"Archimbaud","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0110","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ctrv.2013.03.006","article-title":"Older and new purine nucleoside analogs for patients with acute leukemias","volume":"39","author":"Robak","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.blre.2015.08.001_bb0115","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2174\/156800911796798940","article-title":"Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia","volume":"11","author":"Szmigielska-Kaplon","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.blre.2015.08.001_bb0125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jgo.2013.08.004","article-title":"The role of hypomethylating agents in the treatment of elderly patients with AML","volume":"5","author":"Al-Ali","year":"2014","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.blre.2015.08.001_bb0130","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.leukres.2014.09.001","article-title":"Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts","volume":"38","author":"Srivastava","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0135","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1021\/mp400233x","article-title":"A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine","volume":"10","author":"Zhang","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.blre.2015.08.001_bb0140","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/leu.2014.244","article-title":"Novel drugs for older patients with acute myeloid leukemia","volume":"29","author":"Montalban-Bravo","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2015.08.001_bb0145","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1158\/1535-7163.MCT-13-0956","article-title":"Preclinical characterization of AMG 330, a CD3\/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia","volume":"13","author":"Friedrich","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2015.08.001_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2014.07.002","article-title":"Emerging strategies for high-risk and relapsed\/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials","volume":"29","author":"Sasine","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2015.08.001_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.68","article-title":"Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia","volume":"4","author":"Cummins","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2015.08.001_bb0160","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.3324\/haematol.2014.109975","article-title":"Use of sorafenib for post-transplant relapse in FLT3\/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect","volume":"99","author":"Liegel","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2015.08.001_bb0165","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.2009.25.4888","article-title":"Phase I\/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia","volume":"28","author":"Ravandi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2015.08.001_bb0170","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/leu.2014.54","article-title":"Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia","volume":"28","author":"Ravandi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2015.08.001_bb0175","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3737.3737","article-title":"Evaluation of pharmacokinetic\u2013pharmacodynamic (PKPD) relationship of an oral, selective, first-in-class, potent IDH2 inhibitor, AG-221, from a phase 1 trial in patients with advanced IDH2 mutant positive hematologic malignancies","volume":"124","author":"Fan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0180","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1242\/dmm.015974","article-title":"Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?","volume":"7","author":"Grove","year":"2014","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.blre.2015.08.001_bb0185","doi-asserted-by":"crossref","first-page":"402","DOI":"10.2174\/156800912800190875","article-title":"Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs","volume":"12","author":"Marin","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.blre.2015.08.001_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/aps.2013.131","article-title":"The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy","volume":"35","author":"Marin","year":"2014","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.blre.2015.08.001_bb0195","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00424-003-1103-2","article-title":"The equilibrative nucleoside transporter family, SLC29","volume":"447","author":"Baldwin","year":"2004","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.blre.2015.08.001_bb0200","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00424-003-1107-y","article-title":"The concentrative nucleoside transporter family, SLC28","volume":"447","author":"Gray","year":"2004","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.blre.2015.08.001_bb0205","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/mol.113.086801","article-title":"The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells","volume":"84","author":"Hummel-Eisenbeiss","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.blre.2015.08.001_bb0210","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1172\/JCI110472","article-title":"Cytosine arabinoside influx and nucleoside transport sites in acute leukemia","volume":"69","author":"Wiley","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2015.08.001_bb0215","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0165-6147(98)01253-X","article-title":"Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies","volume":"19","author":"Pastor-Anglada","year":"1998","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.blre.2015.08.001_bb0220","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","article-title":"Mechanisms of resistance to 5-aza-2\u2032-deoxycytidine in human cancer cell lines","volume":"113","author":"Qin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0225","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0145-2126(01)00184-9","article-title":"Potential mechanisms of resistance to cytarabine in AML patients","volume":"26","author":"Galmarini","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0230","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/sj.bjc.6602881","article-title":"The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia","volume":"93","author":"Hubeek","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2015.08.001_bb0235","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/mol.105.015768","article-title":"A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems","volume":"69","author":"King","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.blre.2015.08.001_bb0240","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2002-07-2236","article-title":"Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia","volume":"101","author":"Molina-Arcas","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0245","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/sj.leu.2403582","article-title":"Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells","volume":"19","author":"Molina-Arcas","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2015.08.001_bb0250","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00280-008-0739-1","article-title":"Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures","volume":"63","author":"Elwi","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.blre.2015.08.001_bb0255","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3324\/haematol.2011.051557","article-title":"Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells","volume":"97","author":"Fernandez-Calotti","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2015.08.001_bb0260","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1535-7163.MCT-11-0980","article-title":"Inhibition of OCTN2-mediated transport of carnitine by etoposide","volume":"11","author":"Hu","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2015.08.001_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2012.10.015","article-title":"Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy","volume":"68","author":"Angelini","year":"2013","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0270","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/clpt.2011.102","article-title":"Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia","volume":"90","author":"Yamakawa","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2015.08.001_bb0275","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0280","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2015.08.001_bb0285","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11095-007-9376-3","article-title":"Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells","volume":"25","author":"Hirayama","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0290","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2012-01-405035","article-title":"The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia","volume":"121","author":"Giannoudis","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0295","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","article-title":"Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia","volume":"112","author":"Giannoudis","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0300","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/hep.26425","article-title":"Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib","volume":"58","author":"Herraez","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2015.08.001_bb0305","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1006\/bcmd.2001.0427","article-title":"5-Azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs","volume":"27","author":"Efferth","year":"2001","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2015.08.001_bb0310","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1158\/1535-7163.MCT-06-0086","article-title":"Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia","volume":"5","author":"Efferth","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2015.08.001_bb0315","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/1541-7786.MCR-10-0510","article-title":"c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells","volume":"9","author":"Porro","year":"2011","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0320","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.2006.06390.x","article-title":"Case\u2013control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients","volume":"136","author":"Malagola","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2015.08.001_bb0325","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1365-2141.2000.02354.x","volume":"111","author":"Higashi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2015.08.001_bb0330","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.leukres.2010.01.008","article-title":"Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients","volume":"34","author":"Damiani","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0335","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/sj.leu.2403168","article-title":"Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein","volume":"18","author":"Stam","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2015.08.001_bb0340","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1182\/blood.V91.5.1508","article-title":"Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia","volume":"91","author":"Filipits","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0345","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1158\/1078-0432.CCR-08-0442","article-title":"Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival","volume":"15","author":"Guo","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0350","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/ijc.24207","article-title":"Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs","volume":"124","author":"Oevermann","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2015.08.001_bb0355","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1600-0609.1992.tb01803.x","article-title":"Correlation of MDR1\/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia","volume":"48","author":"Campos","year":"1992","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2015.08.001_bb0360","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bcmd.2007.05.005","article-title":"Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO","volume":"39","author":"Hines","year":"2007","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2015.08.001_bb0365","doi-asserted-by":"crossref","first-page":"428139","DOI":"10.6064\/2012\/428139","article-title":"Plasma membrane transporters in modern liver pharmacology","volume":"2012","author":"Marin","year":"2012","journal-title":"Scientifica"},{"key":"10.1016\/j.blre.2015.08.001_bb0370","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/1354750X.2013.808263","article-title":"MDR1 mRNA expression and MDR1 gene variants as predictors of response to chemotherapy in patients with acute myeloid leukaemia: a meta-analysis","volume":"18","author":"Doxani","year":"2013","journal-title":"Biomarkers"},{"key":"10.1016\/j.blre.2015.08.001_bb0375","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.yexmp.2011.09.004","article-title":"Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy","volume":"92","author":"Chauhan","year":"2012","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.blre.2015.08.001_bb0380","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1158\/1078-0432.CCR-04-0795","article-title":"Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias","volume":"10","author":"Benderra","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0385","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/pgs.12.182","article-title":"Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression","volume":"14","author":"Shi","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.blre.2015.08.001_bb0390","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2011.23","article-title":"Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial","volume":"1","author":"Pallis","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2015.08.001_bb0395","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/sj.leu.2402806","article-title":"Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML","volume":"17","author":"Steinbach","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2015.08.001_bb0400","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00277-008-0439-2","article-title":"CD34+ leukemic subpopulation predominantly displays lower spontaneous apoptosis and has higher expression levels of Bcl-2 and MDR1 genes than CD34\u2212 cells in childhood AML","volume":"87","author":"Shman","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2015.08.001_bb0405","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-007-0269-7","article-title":"CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age","volume":"86","author":"van den Heuvel-Eibrink","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2015.08.001_bb0410","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.leu.2402496","article-title":"Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)","volume":"16","author":"van den Heuvel-Eibrink","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2015.08.001_bb0415","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2003-07-2490","article-title":"Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies","volume":"104","author":"Mahadevan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0420","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3109\/10428194.2011.637214","article-title":"Expression of ABCB5 gene in hematological malignances and its significance","volume":"53","author":"Yang","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2015.08.001_bb0425","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1158\/0008-5472.CAN-04-3327","article-title":"ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma","volume":"65","author":"Frank","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0430","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.leukres.2009.03.028","article-title":"Upregulation of stem cell genes in multidrug resistant K562 leukemia cells","volume":"33","author":"Lehne","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0435","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/10245330701562535","article-title":"Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance","volume":"12","author":"Baran","year":"2007","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2015.08.001_bb0440","doi-asserted-by":"crossref","first-page":"7764","DOI":"10.1158\/1078-0432.CCR-04-1895","article-title":"MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia","volume":"11","author":"Benderra","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0445","first-page":"53","article-title":"Human ABC transporter ABCG2\/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics","volume":"7","author":"Noguchi","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.blre.2015.08.001_bb0450","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/sj.leu.2403395","article-title":"Breast cancer resistance protein (BCRP\/MXR\/ABCG2) in acute myeloid leukemia: discordance between expression and function","volume":"18","author":"Suvannasankha","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2015.08.001_bb0455","doi-asserted-by":"crossref","first-page":"10638","DOI":"10.1016\/S0021-9258(19)50065-5","article-title":"Energy-dependent accumulation of daunorubicin into subcellular compartments of human leukemia cells and cytoplasts","volume":"267","author":"Slapak","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2015.08.001_bb0460","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/leu.2008.103","article-title":"Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration","volume":"22","author":"Chapuy","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2015.08.001_bb0465","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1158\/1078-0432.CCR-05-2587","article-title":"ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia","volume":"12","author":"Steinbach","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0470","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/1078-0432.CCR-09-1321","article-title":"P-glycoprotein (P-gp\/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide","volume":"16","author":"Lagas","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0475","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/10428190290016773","article-title":"The role of drug efflux pumps in acute myeloid leukemia","volume":"43","author":"van der Kolk","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2015.08.001_bb0480","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/jpet.113.205583","article-title":"Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib","volume":"346","author":"Tang","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.blre.2015.08.001_bb0485","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0065-230X(08)60703-4","article-title":"Ara-C: cellular and molecular pharmacology","volume":"72","author":"Grant","year":"1998","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0490","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2217\/pgs.09.118","article-title":"Genetic factors influencing cytarabine therapy","volume":"10","author":"Lamba","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.blre.2015.08.001_bb0495","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2141.2003.04386.x","article-title":"Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine","volume":"122","author":"Galmarini","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2015.08.001_bb0500","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.bcp.2009.03.011","article-title":"Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase\/cytosolic 5\u2032-nucleotidase II expression ratio in primary acute myeloid leukemia cells","volume":"77","author":"Yamauchi","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.blre.2015.08.001_bb0505","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood-2008-05-154302","article-title":"Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity","volume":"113","author":"Hartford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.001_bb0510","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00008571-200411000-00007","article-title":"Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients","volume":"14","author":"Shi","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.blre.2015.08.001_bb0515","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2141.2008.07461.x","article-title":"Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia","volume":"144","author":"Bhatla","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2015.08.001_bb0520","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/pgs.11.149","article-title":"Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia","volume":"13","author":"Abraham","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.blre.2015.08.001_bb0525","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ajh.23549","article-title":"Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase","volume":"88","author":"Falk","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2015.08.001_bb0530","first-page":"2137","article-title":"Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia","volume":"125","author":"Xu","year":"2012","journal-title":"Chin Med J"},{"key":"10.1016\/j.blre.2015.08.001_bb0535","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/sj.leu.2401175","article-title":"Mechanisms of cellular anthracycline resistance in childhood acute leukemia","volume":"12","author":"Den Boer","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2015.08.001_bb0540","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0006-2952(99)00322-6","article-title":"Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction","volume":"59","author":"Ax","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.blre.2015.08.001_bb0545","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mrfmmm.2008.12.010","article-title":"The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis","volume":"662","author":"Birtwistle","year":"2009","journal-title":"Mutat Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0550","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.taap.2014.04.027","article-title":"Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3","volume":"278","author":"Hofman","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.blre.2015.08.001_bb0555","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.leukres.2006.10.002","article-title":"The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia","volume":"31","author":"Barragan","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0560","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0026-895X(25)09935-3","article-title":"O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4","volume":"45","author":"Relling","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.blre.2015.08.001_bb0565","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0022-3565(24)37724-9","article-title":"A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes","volume":"286","author":"Kawashiro","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.blre.2015.08.001_bb0570","first-page":"7777","article-title":"Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase","volume":"61","author":"Kagan","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2015.08.001_bb0575","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1124\/dmd.106.012732","article-title":"UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics","volume":"35","author":"Wen","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.blre.2015.08.001_bb0580","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0022-3565(24)39096-2","article-title":"The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance","volume":"294","author":"O'Brien","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.blre.2015.08.001_bb0585","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bcp.2012.04.001","article-title":"Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites","volume":"84","author":"Ghassabian","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.blre.2015.08.001_bb0590","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1158\/1078-0432.CCR-11-2484","article-title":"Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia","volume":"18","author":"Peer","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X15000612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X15000612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T01:11:38Z","timestamp":1748567498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X15000612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0268960X15000612"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2015.08.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2015.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}